NEW YORK (GenomeWeb News) — Stratagene today said third-quarter revenues decreased 2 percent as an unfavorable court decision caused net losses to balloon 817 percent.

 

Total receipts for the three months ended Sept. 30 decreased to $23.2 million from $23.7 million year over year. The company blamed part of the slide on declining sales in its gene-discovery and cloning systems products.

 

R&D spending remained flat at around $2.8 million.